Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator?
Sphingosine 1-phosphate (S1P) concentration in plasma and serum has been estimated to be within 200-900 nM. Among plasma and serum components, S1P is concentrated in lipoprotein fractions with a rank order of high-density lipoprotein (HDL)>low-density lipoprotein (LDL)>very low-density lipoprotein (VLDL)>lipoprotein-deficient plasma (LPDP) when expressed as the per unit amount of protein. It is well known that LDL, especially oxidized LDL, is closely correlated and HDL is inversely correlated, with the risk of cardiovascular disease, such as atherosclerosis. Evidence was presented that a part of HDL-induced actions previously reported are mediated by the lipoprotein-associated S1P. Furthermore, S1P content in LDL was markedly decreased during its oxidation. This paper will discuss whether S1P is an atherogenic mediator or an anti-atherogenic mediator.
Okajima
Fumikazu
F
Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, 3-39-15 Showa-machi, Maebashi, Japan. fokajima@showa.gunma-u.ac.jp
D000818:Animals; D001161:Arteriosclerosis / Q000503:physiopathology* / Q000517:prevention & control; D002352:Carrier Proteins / Q000097:blood*; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008246:Lysophospholipids; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000097:blood*
D002352:Carrier Proteins; D008074:Lipoproteins; D008246:Lysophospholipids; C060506:sphingosine 1-phosphate; D013110:Sphingosine